Lonza: UBS maintains 'buy' rating

(CercleFinance.com) - UBS reaffirms its "buy" recommendation on Lonza Group and its price target of CHF630, a target which implies a 27% growth potential for the share of the Swiss chemicals and pharmaceutical subcontracting group.


Following a roadshow with the group's executives, the broker is part of " Optimism on the commercial manufacturing outlook and biotech funding challenges likely to persist into 2024 ".

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.